# Mabion

Source: https://onco.cc/companies/mabion/  
OnCo record `mabion` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Mabion is a Polish biotech near Łódź that developed a rituximab biosimilar, MabionCD20, through phase 3 trials in lymphoma and rheumatoid arthritis, and now also manufactures biologics for partners.

## Summary

Mabion S.A., based in Konstantynów Łódzki and listed in Warsaw, built a biologics plant to develop and make biosimilar antibodies. Its rituximab biosimilar MabionCD20 was taken through phase 3 comparative trials in diffuse large B-cell lymphoma and rheumatoid arthritis, registered on ClinicalTrials.gov under Mabion as lead sponsor, and the company now also offers contract manufacturing.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Mabion SA; Mabion S.A.
- Tags: ctgov-sponsor
- HQ: Konstantynów Łódzki
- Type: biotech
- Website: https://www.mabion.eu

## Sources

- Official website: https://www.mabion.eu
- ClinicalTrials.gov: trials led by Mabion SA: https://clinicaltrials.gov/search?lead=Mabion%20SA
- Wikidata: https://www.wikidata.org/wiki/Q19653276

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- drugs: [Rituximab](https://onco.cc/drugs/rituximab/)
- terms: [Biosimilar](https://onco.cc/terms/biosimilar/), [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/mabion.json